Connect with us

Business

The Paycheck Protection Program expires today. The future of the small business rescue plan is in limbo as stimulus talks stall – USA TODAY

Lawmakers are discussing an extension of the PPP but talks are stalled amid a stalemate over another round of COVID-19 pandemic stimulus relief.

Published

on

post featured image

Business

Feels like a ‘classic October crash’ is on the way, market strategist warns – MarketWatch

Published

on

post featured image

Thats Bill Blain, strategist at London-based Shard Capital, sharing his ominous take on the stock market on Thursday ahead of what he described as the most critical election in global history and as investors grapple with spiking coronavirus numbers.Winter lockdowns, fears about second and now third waves of infections, and tumbling stocks on the back of prospects for a crumbling economic recovery across Europe have put markets into full tumble mode, he wrote in a blog post. It might be the last…

Click here to view the original article.

Continue Reading

Business

Iconic SF skyscraper sells for the first time ever – SF Gate

Deutsche Finance America and New York developer Michael Shvo teamed up to buy the…

Published

on

post featured image

San Francisco’s iconic Transamerica Pyramid sold for the first time in its nearly 50-year history Wednesday, with with Deutsche Finance America and New York developer Michael Shvo joining forces to purchase the tower and complex for $650 million.The sale of the 48-story skyscraper and the complex that covers an entire city block marks “the largest commercial transaction in the U.S. since the onset of the Covid-19 pandemic,” Forbes reported.“We’re proud to take on ownership and management of the…

Click here to view the original article.

Continue Reading

Business

Moderna Stock Jumps as Biotech Rakes in Revenue for Covid Vaccine – Barron’s

Published

on

post featured image

Modernas
efforts to develop the first Covid-19 vaccine led to a big jump in third-quarter research and development costs, as well as soaring revenue.The Cambridge, Mass.-based biotech company, which doesnt yet have a commercial product but is among the companies chasing approval for a coronavirus vaccine, reported third-quarter earnings Thursday morning. It had a loss of 59 cents a share on revenue of $157.9 million. Revenue, which was boosted mostly by grants for Covid vaccine development, was…

Click here to view the original article.

Continue Reading

Trending